Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.

Clinical colorectal cancer - 1 Dec 2014

Cercek Andrea, Shia Jinru, Gollub Marc, Chou Joanne F, Capanu Marinela, Raasch Pamela, Reidy-Lagunes Diane, Proia David A, Vakiani Efsevia, Solit David B, Saltz Leonard B

Abstract excerpt

BACKGROUND: Heat shock protein 90 (Hsp90) is a cellular chaperone that is required for the maturation and stability of a variety of proteins that play key roles in colon cancer initiation and progression. The primary objective of the current study was to define the safety and efficacy of ganetespib, a novel, selective small-molecule Hsp90 inhibitor, in patients with refractory metastatic colorectal cancer....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HSP90 Heat-Shock Proteins
Share to Immunoenzyme Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Salvage Therapy

Share to Survival Rate

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 25444464
DOI: 10.1016/j.clcc.2014.09.001
PMCID: PMC5489410

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.PMID 25444464Read ↗

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.Semantic proximity Read ↗

Strong Hsp90α/β Protein Expression in Advanced Primary CRC Indicates Short Survival and Predicts Response to the Hsp90α/β-Specific Inhibitor PimitespibSemantic proximity Read ↗

Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.Semantic proximity Read ↗

Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.Semantic proximity Read ↗

Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network.Semantic proximity Read ↗

Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.Semantic proximity Read ↗

Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.Semantic proximity Read ↗

A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

High expression of HSP90 is associated with poor prognosis in patients with colorectal cancerSemantic proximity Read ↗

Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis.Semantic proximity Read ↗

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.Semantic proximity Read ↗

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.